Shannon Gwin Mitchell, Ph.D.
Dr. Mitchell, Research Scientist at FRI, has been conducting community-based research with drug-addicted individuals for more than 10 years. From 1998 through 2006, Dr. Mitchell was a qualitative researcher at the Johns Hopkins Bloomberg School of Public Health on numerous HIV risk-reduction interventions focusing on injection drug users. While at Hopkins, she contributed to process evaluations and exploratory research involving study participants and members of their social/risk networks.
In 2006, Dr. Mitchell joined FRI to assume primary responsibility for the qualitative component of a NIDA-funded study, led by Dr. Robert Schwartz, examining methadone treatment entry and engagement. Dr. Mitchell is currently the Principal Investigator on a NIDA-funded study comparing intensive outpatient v. standard outpatient counseling when combined with buprenorphine for heroin-dependent African Americans. This study was one of only about 1% of 20,000 NIH Challenge Grant applications selected for funding through the American Recovery and Reinvestment Act of 2009. Dr. Mitchell is also the Co-Investigator on a randomized controlled trial comparing the effectiveness of a computerized brief intervention for substance use to a ‘standard practice’ interpersonal brief intervention.
Dr. Mitchell is a member of the American Public Health Association, the Society for Community Research and Action (Division 27 of APA), and the Society for Applied Anthropology. She recently guest edited a special issue of the American Journal of Community Psychology (Dec 2009) along with Dr. David Lounsbury of the Albert Einstein College of Medicine at Yeshiva University. The special issue focused on social ecological approaches to community health research and action. Dr. Mitchell has over 20 publications in the areas of HIV prevention and substance abuse treatment for injection-drug users, as well as employee health and stress issues.
Timothy W. Kinlock, Ph.D.
Dr. Kinlock has considerable expertise and experience in developing, implementing, and evaluating innovative drug abuse treatment interventions for prison inmates with histories of heroin addiction. He is a leading US researcher in the field of pharmacotherapy among patients in the criminal justice system. He has studied every approved medication for the treatment of opioid dependence among prisoners or parolees and probationers including buprenorphine, LAAM, methadone, and naltrexone. Dr. Kinlock is a member of the American Society of Criminology and the Committee on Problems of Drug Dependence. In 2006, his biography was accepted for publication in Marquis’ Who’s Who in America.
Cathy Reback, Ph.D.
Cathy Reback received her Ph.D. in Sociology from the University of California, Santa Cruz in 1986. Dr. Reback is both a researcher and community provider. In addition to her work as a Research Sociologist and Principal Investigator with Friends Research Institute, she is an Associate Research Sociologist with UCLA Integrated Substance Abuse Programs (UCLA ISAP) and a Core Scientist with the UCLA Center for HIV Identification, Prevention and Treatment Services (UCLA CHIPTS). Additionally, in 1994, Dr. Reback founded the Prevention Division of the Van Ness Recovery House, which provides HIV and substance abuse prevention programs to out-of-treatment substance users, and continues to serve as its Director.
Currently, Dr. Reback is Principal Investigator on a NIDA-funded study to assess the efficacy of a contingency management for increasing prosocial and healthy behavior and reducing substance abuse among non-treatment seeking substance users, a California HIV/AIDS Research Programs (CHRP)-funded study evaluating a combined evidenced-based cognitive behavioral therapy and contingency management intervention for producing sustained HIV sexual and drug risk reductions among gay and bisexual methamphetamine users (www.friendslabrea.org), and a CDC-funded study evaluating the feasibility and efficacy of an information technology (IT) communication intervention for out-of-treatment MSM methamphetamine users. Additionally, Dr. Reback is the Director of six county and city-funded HIV risk reduction programs for gay, bisexual and MSM substance users and high-risk transgender women.
Elizabeth C. Katz, Ph.D.
Dr. Katz is a Senior Research Scientist at the Social Research Center and an Assistant Professor and Director of the Master’s in Clinical Psychology Program at Towson University. She is also a licensed clinical psychologist and mother of two delightful daughters (ages 5 and 11). She has extensive experience treating substance abusing, criminal-justice involved, and mental health patients. In addition, she has spent much of her career training and supervising clinicians working with these same populations. Her research interests include enhancing entry and engagement in treatment of substance dependent patients, improving treatment outcomes and reintegration of drug-involved offenders, and developing and evaluating treatment approaches that are theoretically-based and feasible for implementation within community treatment settings. She is principal investigator on a NIDA-funded study examining role induction as a strategy for facilitating the transition of opioid-addicted outpatients from a 30-day buprenorphine detoxification into longer-term drug-free treatment. Dr. Katz is co-investigator on another NIDA-funded study designed to develop and evaluate behavioral therapies for reducing substance use and recidivism for drug-involved offenders.
In association with NIDA- and SAMHSA-funded research, Dr. Katz has developed several detailed therapy manuals for treating substance dependent patients entering drug-free treatment or enrolled in detoxification; substance dependent adolescents; and drug-involved parolees and probationers. She has also been responsible for training of clinical and Parole and Probation staff who are delivering these interventions. Dr. Katz has also delivered several well-received workshops on the Role Induction intervention she developed with her colleagues, Dr. Barry Brown and Dr. Robert Schwartz. Dr. Katz is a member of the American Psychological Association and the College on Problems of Drug Dependence.